Opus Genetics (IRD) Net Equity Issued and Repurchased (2011 - 2026)
Opus Genetics (IRD) posted quarterly Net Equity Issued and Repurchased of $2.2 million for Q1 2026, up 450.12% year-over-year from $409000.0 in Q1 2025, and up 1156.98% quarter-over-quarter from $179000.0 in Q4 2025.
Opus Genetics (IRD) Net Equity Issued and Repurchased (2011 - 2026) Analysis & Trends
Opus Genetics (IRD) has reported Net Equity Issued and Repurchased for 13 consecutive years, with $2.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Equity Issued and Repurchased rose 450.12% year-over-year to $2.2 million; the TTM figure through Mar 2026 stood at $4.5 million (down 25.86% YoY), while the FY2025 annual figure was $5.8 million, up 29.09% from the prior year.
- Net Equity Issued and Repurchased rose to $2.2 million in Q1 2026 per IRD's latest filing, from $179000.0 in the prior quarter.
- Across five years, Net Equity Issued and Repurchased topped out at $5.2 million in Q3 2024 and bottomed at $28000.0 in Q4 2022.
- Historically, Net Equity Issued and Repurchased has averaged $1.9 million across 5 years, with a median of $1.5 million in 2022.
- Annual changes were most pronounced in 2022 — Net Equity Issued and Repurchased sank 99.88% — and 2023, when it soared 13275.0%.
- Opus Genetics' Net Equity Issued and Repurchased stood at $28000.0 in 2022, then jumped by 13275.0% to $3.7 million in 2023, then surged by 38.85% to $5.2 million in 2024, then sank by 96.56% to $179000.0 in 2025, then soared by 1156.98% to $2.2 million in 2026.
- Business Quant data shows IRD's Net Equity Issued and Repurchased at $2.2 million in Q1 2026, $179000.0 in Q4 2025, and $1.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 141.90 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Opus Genetics | 298.36 Mn | 209.55 Mn | - | 2.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.30 Mn |
| Jun 30, 2026 | 2.30 Mn |
| Mar 31, 2026 | 2.25 Mn |
| Mar 31, 2026 | 2.25 Mn |
| Dec 31, 2025 | 179,000.00 |
| Dec 31, 2025 | 179,000.00 |
| Sep 30, 2025 | 1.70 Mn |
| Sep 30, 2025 | 1.70 Mn |
| Jun 30, 2025 | 400,000.00 |
| Jun 30, 2025 | 400,000.00 |
| Mar 31, 2025 | 409,000.00 |
| Mar 31, 2025 | 409,000.00 |
| Sep 30, 2024 | 5.20 Mn |
| Sep 30, 2024 | 5.20 Mn |
| Jun 30, 2024 | 500,000.00 |
| Jun 30, 2024 | 500,000.00 |
| Mar 31, 2024 | 4.80 Mn |
| Mar 31, 2024 | 4.80 Mn |
| Dec 31, 2023 | 3.75 Mn |
| Dec 31, 2023 | 3.75 Mn |